医药魔方2023-07-26 10:06
7月24日,Syndax Pharmaceuticals和Incyte共同宣布,抗CSF-1R单抗axatilimab在既往接受过二线及以上治疗后疾病进展的慢性移植物抗宿主病(GVHD)成人和儿童患者中的II期AGAVE-201研究取得了积极的关键数据。
网页链接{点...查看全文
产业链观察2023-07-26 01:35
#药闻简讯# 7月24日,$Syndax制药(SNDX)$ 和$因塞特医疗(INCY)$ 共同宣布,抗CSF-1R单抗axatilimab在既往接受过二线及以上治疗后疾病进展的慢性移植物抗宿主病(GVHD)成人和儿童患者中的II期AGAVE-201研究取得了积极的关键数据。
AGAVE-201研究是一项随机、开放标签的II期临床试验,共纳入241...查看全文
SeekingBiotech2023-07-24 22:03
SNDX and Incyte announced topline data from the pivotal AGAVE-201 trial of axatilimab in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy. The trial achieved its primary endpoint across all cohorts
$S...查看全文
智通财经APP获悉,当地时间6月13日,美国FDA宣布批准礼来(LLY.US)和因塞特(INCY.US)联合开发的口服JAK抑制剂巴瑞替尼(英文商品名Olumiant)上市,用于治疗严重斑秃成人患者。值得一提的是,这是美国FDA批准用于治疗斑秃的首款系统性疗法... 网页链接
智通财经APP获悉,美国FDA于当地时间7月29日扩大了礼来(LLY.US)与因塞特医疗(INCY.US)的baricitinib药物(商用名Olumiant)的紧急适用授权(EUA)。根据修订后的EUA,治疗确诊新冠的住院患者时,baricitinib不需与吉利德科学(GILD.US)的Vekl... 网页链接
$因塞特医疗(INCY)$ 内部交易: 2021-12-23,Director,DIXON WENDY L ,卖出,20000普通股, $22.05
$因塞特医疗(INCY)$ 内部交易: 2021-12-23,Director,DIXON WENDY L ,期权,20000普通股, $73.25
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-071241 Size: 9 KB 网页链接
$因塞特医疗(INCY)$ 内部交易: 2021-12-17,Director,BAKER BROS. ADVISORS LP ,买入,1075872普通股, $72.80
$因塞特医疗(INCY)$ 内部交易: 2021-12-16,Director,BAKER BROS. ADVISORS LP ,买入,169315普通股, $71.96
$因塞特医疗(INCY)$ 内部交易: 2021-12-15,Director,BAKER BROS. ADVISORS LP ,买入,350332普通股, $71.51
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-21-006085 Size: 43 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-069427 Size: 5 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-066435 Size: 8 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-066430 Size: 8 KB 网页链接